Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen:
doi:10.22028/D291-34105
Titel: | Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study |
VerfasserIn: | Stege, Henner Haist, Maximilian Schultheis, Michael Fleischer, Maria Isabel Mohr, Peter Meier, Friedegund Schadendorf, Dirk Ugurel, Selma Livingstone, Elisabeth Zimmer, Lisa Herbst, Rudolf Pföhler, Claudia Kähler, Katharina Weichenthal, Michael Terheyden, Patrick Nashan, Dorothée Debus, Dirk Kaatz, Martin Ziller, Fabian Haferkamp, Sebastian Forschner, Andrea Leiter, Ulrike Kreuter, Alexander Ulrich, Jens Kleemann, Johannes Bradfisch, Fabienne Grabbe, Stephan Loquai, Carmen |
Sprache: | Englisch |
Titel: | Cancers |
Bandnummer: | 13 |
Heft: | 10 |
Verlag/Plattform: | MDPI |
Erscheinungsjahr: | 2021 |
Freie Schlagwörter: | targeted therapy complete response advanced melanoma discontinuation disease progression second-line immunotherapy |
DDC-Sachgruppe: | 610 Medizin, Gesundheit |
Dokumenttyp: | Journalartikel / Zeitschriftenartikel |
Abstract: | The advent of BRAF/MEK inhibitors (BRAFi/MEKi) has significantly improved progressionfree (PFS) and overall survival (OS) for patients with advanced BRAF-V600-mutant melanoma. Long-term survivors have been identified particularly among patients with a complete response (CR) to BRAF/MEK-directed targeted therapy (TT). However, it remains unclear which patients who achieved a CR maintain a durable response and whether treatment cessation might be a safe option in these patients. Therefore, this study investigated the impact of treatment cessation on the clinical course of patients with a CR upon BRAF/MEK-directed-TT. We retrospectively selected patients with BRAF-V600-mutant advanced non-resectable melanoma who had been treated with BRAFi ± MEKi therapy and achieved a CR upon treatment out of the multicentric skin cancer registry ADOReg. Data on baseline patient characteristics, duration of TT, treatment cessation, tumor progression (TP) and response to second-line treatments were collected and analyzed. Of 461 patients who received BRAF/MEK-directed TT 37 achieved a CR. TP after initial CR was observed in 22 patients (60%) mainly affecting patients who discontinued TT (n = 22/26), whereas all patients with ongoing TT (n = 11) maintained their CR. Accordingly, patients who discontinued TT had a higher risk of TP compared to patients with ongoing treatment (p < 0.001). However, our data also show that patients who received TT for more than 16 months and who discontinued TT for other reasons than TP or toxicity did not have a shorter PFS compared to patients with ongoing treatment. Response rates to second-line treatment being initiated in 21 patients, varied between 27% for immune-checkpoint inhibitors (ICI) and 60% for BRAFi/MEKi rechallenge. In summary, we identified a considerable number of patients who achieved a CR upon BRAF/MEK-directed TT in this contemporary realworld cohort of patients with BRAF-V600-mutant melanoma. Sustained PFS was not restricted to ongoing TT but was also found in patients who discontinued TT. |
DOI der Erstveröffentlichung: | 10.3390/cancers13102312 |
Link zu diesem Datensatz: | urn:nbn:de:bsz:291--ds-341058 hdl:20.500.11880/31362 http://dx.doi.org/10.22028/D291-34105 |
ISSN: | 2072-6694 |
Datum des Eintrags: | 26-Mai-2021 |
Bezeichnung des in Beziehung stehenden Objekts: | Supplementary Materials |
In Beziehung stehendes Objekt: | https://www.mdpi.com/article/10.3390/cancers13102312/s1 |
Fakultät: | M - Medizinische Fakultät |
Fachrichtung: | M - Dermatologie |
Professur: | M - Keiner Professur zugeordnet |
Sammlung: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Dateien zu diesem Datensatz:
Datei | Beschreibung | Größe | Format | |
---|---|---|---|---|
cancers-13-02312.pdf | 1,28 MB | Adobe PDF | Öffnen/Anzeigen |
Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons